ADC Therapeutics SA (ADCT) vs Alkermes (ALKS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Alkermes (ALKS) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 29.4% versus a loss of 62.3%. Over five years, ALKS leads with a +28.2% price change compared with -93.2% for ADCT. Alkermes is the larger company by market cap ($6.81 billion vs $220.9 million), about 30.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | ALKS |
|---|---|---|
| Share price | $1.73 | $40.61 |
| Market cap | $220.87M | $6.81B |
| 1-day change | +8.81% | +1.25% |
| YTD return | -50.99% | +45.14% |
| 1-year return | -62.31% | +29.41% |
| 5-year return | -93.21% | +28.23% |
| P/E ratio (TTM) | — | 106.87 |
| Forward P/E | — | 22.46 |
| EPS (TTM) | $-0.60 | $0.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.48B |
| Revenue growth (YoY) | — | -5.25% |
| Net income (latest FY) | — | $241.66M |
| Gross margin | — | 86.69% |
| Operating margin | — | 17.21% |
| Net margin | — | 16.37% |
| 52-week high | $4.98 | $55.67 |
| 52-week low | $0.78 | $27.00 |
| Distance from 52-week high | -65.26% | -27.05% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +92.49% | +38.59% |
| Average volume | 1.43M | 1.86M |
| Shares outstanding | 127.67M | 167.76M |
| Employees | 188 | 2,050 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alkermes is about 30.8 times larger than ADC Therapeutics SA by market value ($6.81B vs $220.87M).
- ALKS has outperformed ADCT by 91.7 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Healthcare · Drug Manufacturers - Specialty & Generic · 188 employees
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Healthcare · Drug Manufacturers - Specialty & Generic · 2,050 employees
ADCT vs ALKS FAQ
Which is bigger, ADC Therapeutics SA or Alkermes?
Alkermes (ALKS) is larger, with a market capitalization of $6.81B compared with $220.87M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or ALKS?
ALKS returned +29.41% over the past 12 months, compared with -62.31% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Alkermes in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.